Otsuka Announces Plans to Buy Avanir for $3.5 Billion
Japanese drugmaker Otsuka announced plans to buy CNS-specialist Avanir Pharmaceuticals for $3.5 billion in an all-cash tender offer.
Otsuka Pharmaceutical announced on Dec. 2, 2014 that it had reached an agreement in which Otsuka America, its US subsidiary, would acquire Avanir Pharmaceuticals for $3.5 billion. Avanir, a biopharmaceutical company specializing in central nervous system (CNS) diseases, is the US-based manufacturer of Nuedexta, the only FDA-approved treatment for the neurological disease pseudobulbar affect (PBA). PBA is a neurological disease characterized by sudden and uncontrollable laughing or crying, secondary to a neurological condition such as traumatic brain injury, multiple sclerosis, Parkinson’s, a stroke, or Alzheimer’s disease
Under the agreement, Otsuka will obtain rights to Nuedexta, as well as AVP-786, a late-stage investigational compound developed to treat agitation associated with Alzheimer’s.
Source: Otsuka
British Patient Capital Invests £10 Million in Maxion Therapeutics, Part of Series A Financing Round
March 27th 2025The £10 million (US$13 million) investment is part of a larger £58 million (US$75 million) Series A financing round to be used for the development of Maxion Therapeutics’ preclinical lead program for treating inflammatory diseases.
